Handelsbanken Fonder
CTKB icon

Handelsbanken Fonder’s Cytek Biosciences CTKB Stock Holding History

Handelsbanken Fonder’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-16,800
Closed -$93K – 1568
2023
Q3 		$93K Hold
16,800
– – ﹤0.01% 1549
2023
Q2 		$143K Buy
+16,800
New +$151K ﹤0.01% 1542

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $71.6B AUM 29.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Handelsbanken Fonder's CTKB Position: Q4 2023 in Review

Handelsbanken Fonder sold out of Cytek Biosciences (CTKB) in Q4 2023, closing a stake of 16,800 shares — an estimated $93K sold.

Handelsbanken Fonder first reported a position in CTKB in Q2 2023 and held it in 2 quarters. The position peaked at $143K in Q2 2023. 105 funds tracked by Wall St. Rank hold CTKB as of Q4 2023.

  • Handelsbanken Fonder reported no remaining Cytek Biosciences position as of Q4 2023 after selling out during the quarter.
  • Handelsbanken Fonder sold 16,800 Cytek Biosciences shares in Q4 2023, an estimated $93K.
  • Handelsbanken Fonder first reported a position in Cytek Biosciences in Q2 2023 and held it in 2 quarters.
  • Handelsbanken Fonder's Cytek Biosciences position peaked at $143K in Q2 2023.
  • 105 funds tracked by Wall St. Rank held Cytek Biosciences as of Q4 2023.

Based on Handelsbanken Fonder's 13F filing for Q4 2023, filed 1 Feb 2024.